About the study medicine
Pfizer is investigating a study medicine, PF-08634404, which is a bispecific antibody that was designed to target both PD-1 and VEGF to potentially block immune checkpoints and inhibit angiogenesis. This dual mechanism has the potential to achieve tumor immunosurveillance, while disrupting vascular support for tumor progression, compared with blocking either target alone in patients with solid tumors.
The study medicine is currently being studied in various cancer types, including lung, colorectal, urothelial, renal, and hepatocellular carcinomas, as well as other advanced solid tumors.
Our clinical trials
Explore Pfizer’s novel investigational PD-1 x VEGF bispecific antibody program, which is a series of clinical trials evaluating a bispecific antibody that was designed to target both PD-1 and VEGF.
A Phase 3 clinical trial evaluating PF-08634404 combined with chemotherapy or pembrolizumab combined with chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer in your patients who are not candidates for surgical resection and curative concurrent/sequential chemoradiotherapy.
A Phase 3 clinical trial evaluating PF-08634404 or bevacizumab combined with chemotherapy in your patients with metastatic colorectal cancer who have not received prior systemic treatment for metastatic disease.
A Phase 2/3 clinical trial of PF-08634404 combined with chemotherapy in extensive-stage small cell lung cancer for your patients who have not received prior systemic therapy for ES-SCLC.
A Phase 1b/2 clinical trial of PF-08634404 as monotherapy and combination therapy with ipilimumab or axitinib for your patients with locally advanced or metastatic renal cell carcinoma who have received no previous systemic therapy for RCC.
A Phase 1b/2 clinical trial of PF-08634404 as monotherapy and in combination with ipilimumab for your patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma.
A Phase 1b/2 clinical trial of PF-08634404 in combination with different anticancer agents in your patients with advanced solid tumors. The clinical trial currently includes combinations of PF-08634404 with different antibody drug conjugates (ADCs) in treatment-naive patients with locally advanced or metastatic non-small cell lung cancer without actionable genomic alterations.